JP2022522550A5 - - Google Patents

Info

Publication number
JP2022522550A5
JP2022522550A5 JP2020564221A JP2020564221A JP2022522550A5 JP 2022522550 A5 JP2022522550 A5 JP 2022522550A5 JP 2020564221 A JP2020564221 A JP 2020564221A JP 2020564221 A JP2020564221 A JP 2020564221A JP 2022522550 A5 JP2022522550 A5 JP 2022522550A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020564221A
Other languages
English (en)
Japanese (ja)
Other versions
JP7610410B2 (ja
JP2022522550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/051958 external-priority patent/WO2020183318A1/en
Publication of JP2022522550A publication Critical patent/JP2022522550A/ja
Priority to JP2024165292A priority Critical patent/JP2024178360A/ja
Publication of JP2022522550A5 publication Critical patent/JP2022522550A5/ja
Application granted granted Critical
Publication of JP7610410B2 publication Critical patent/JP7610410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564221A 2019-03-08 2020-03-06 副甲状腺ホルモンアナログの経口製剤および治療 Active JP7610410B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024165292A JP2024178360A (ja) 2019-03-08 2024-09-24 副甲状腺ホルモンアナログの経口製剤および治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921009082 2019-03-08
IN201921009082 2019-03-08
PCT/IB2020/051958 WO2020183318A1 (en) 2019-03-08 2020-03-06 Oral formulation and treatment of pth analog.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024165292A Division JP2024178360A (ja) 2019-03-08 2024-09-24 副甲状腺ホルモンアナログの経口製剤および治療

Publications (3)

Publication Number Publication Date
JP2022522550A JP2022522550A (ja) 2022-04-20
JP2022522550A5 true JP2022522550A5 (https=) 2024-10-28
JP7610410B2 JP7610410B2 (ja) 2025-01-08

Family

ID=72426161

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564221A Active JP7610410B2 (ja) 2019-03-08 2020-03-06 副甲状腺ホルモンアナログの経口製剤および治療
JP2024165292A Pending JP2024178360A (ja) 2019-03-08 2024-09-24 副甲状腺ホルモンアナログの経口製剤および治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024165292A Pending JP2024178360A (ja) 2019-03-08 2024-09-24 副甲状腺ホルモンアナログの経口製剤および治療

Country Status (6)

Country Link
US (1) US20220133857A1 (https=)
JP (2) JP7610410B2 (https=)
KR (1) KR20210137373A (https=)
CN (1) CN111971027A (https=)
TW (1) TWI821541B (https=)
WO (1) WO2020183318A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137373A (ko) * 2019-03-08 2021-11-17 안야 바이오팜 인코포레이티드 부갑상샘 호르몬 유사체의 경구 제제 및 치료
EP4226918A1 (en) * 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
KR102844771B1 (ko) * 2022-07-22 2025-08-12 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법
WO2025037993A1 (en) 2023-08-13 2025-02-20 Filip Majewski Dosage form for peptide agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1228708A (zh) * 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
US6946151B2 (en) * 2002-11-12 2005-09-20 Ayurvedic-Life International, Llc Therapeutic compositions
US20040121025A1 (en) * 2002-12-20 2004-06-24 Mckee Dwight Oral composition for the treatment and prevention of bone loss
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
JP5324781B2 (ja) * 2004-06-14 2013-10-23 ビーエーエスエフ、ビューティー、ケア、ソルーションズ、フランス、エスエーエス Pth断片含有化粧品
JP5740689B2 (ja) * 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー. タンパク質の経口投与用の方法および組成物
EP3016674A4 (en) * 2013-06-23 2017-03-15 Wisconsin Alumni Research Foundation Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
US20180036382A1 (en) * 2015-02-09 2018-02-08 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
JP2018529749A (ja) * 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
TWI751379B (zh) * 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
KR20210137373A (ko) * 2019-03-08 2021-11-17 안야 바이오팜 인코포레이티드 부갑상샘 호르몬 유사체의 경구 제제 및 치료

Similar Documents

Publication Publication Date Title
JP2023512297A5 (https=)
JP2021008630A5 (https=)
JP2023538015A5 (https=)
JP2022544589A5 (https=)
JP2024510476A5 (https=)
JP2020175021A5 (https=)
JPWO2021171942A5 (https=)
JP2024510228A5 (https=)
JP2020183924A5 (https=)
JPWO2021201293A5 (https=)
JP2021512134A5 (https=)
JP2022522550A5 (https=)
JP2020180208A5 (https=)
JP2020043052A5 (https=)
JP2022540681A5 (https=)
JP2024077017A5 (https=)
JP2024076480A5 (https=)
JP2023176349A5 (https=)
JP2022120819A5 (https=)
JP2020147467A5 (https=)
JP2020135963A5 (https=)
JPWO2022054956A5 (https=)
JPWO2022162814A5 (https=)
JPWO2021152968A5 (https=)
JPWO2024024534A5 (https=)